Personalis ROA 2018-2026 | PSNL
Current and historical return on assets (ROA) values for Personalis (PSNL) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Personalis ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2026-03-31 | $-0.10B | $0.29B | -33.07% |
| 2025-12-31 | $-0.08B | $0.28B | -29.58% |
| 2025-09-30 | $-0.07B | $0.26B | -28.33% |
| 2025-06-30 | $-0.09B | $0.26B | -34.93% |
| 2025-03-31 | $-0.08B | $0.24B | -34.67% |
| 2024-12-31 | $-0.08B | $0.22B | -36.36% |
| 2024-09-30 | $-0.09B | $0.21B | -43.50% |
| 2024-06-30 | $-0.08B | $0.21B | -39.38% |
| 2024-03-31 | $-0.09B | $0.22B | -41.52% |
| 2023-12-31 | $-0.11B | $0.24B | -44.81% |
| 2023-09-30 | $-0.11B | $0.26B | -43.42% |
| 2023-06-30 | $-0.11B | $0.28B | -38.87% |
| 2023-03-31 | $-0.11B | $0.31B | -36.74% |
| 2022-12-31 | $-0.11B | $0.34B | -33.48% |
| 2022-09-30 | $-0.10B | $0.36B | -28.06% |
| 2022-06-30 | $-0.09B | $0.39B | -24.37% |
| 2022-03-31 | $-0.08B | $0.39B | -20.66% |
| 2021-12-31 | $-0.07B | $0.40B | -16.42% |
| 2021-09-30 | $-0.06B | $0.36B | -16.21% |
| 2021-06-30 | $-0.05B | $0.32B | -15.71% |
| 2021-03-31 | $-0.04B | $0.26B | -16.99% |
| 2020-12-31 | $-0.04B | $0.20B | -20.71% |
| 2020-09-30 | $-0.04B | $0.18B | -19.89% |
| 2020-06-30 | $-0.03B | $0.15B | -20.81% |
| 2020-03-31 | $-0.03B | $0.17B | -17.55% |
| 2019-12-31 | $-0.03B | $0.13B | -20.43% |
| 2019-06-30 | $-0.02B | $0.05B | -33.33% |
| 2019-03-31 | $-0.02B | 0 | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.630B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |